Bank of New York Mellon Corp boosted its stake in Becton, Dickinson and Company (NYSE:BDX) by 0.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,002,287 shares of the medical instruments supplier’s stock after buying an additional 2,392 shares during the period. Bank of New York Mellon Corp owned 0.94% of Becton, Dickinson and worth $390,667,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of BDX. BlackRock Inc. lifted its holdings in Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after buying an additional 15,887,611 shares during the period. Vanguard Group Inc. lifted its holdings in Becton, Dickinson and by 5.3% in the first quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock worth $2,917,094,000 after buying an additional 796,034 shares during the period. Point72 Asset Management L.P. purchased a new stake in Becton, Dickinson and in the first quarter worth about $101,993,000. Waverton Investment Management Ltd purchased a new stake in Becton, Dickinson and in the second quarter worth about $68,448,000. Finally, Montag & Caldwell LLC lifted its holdings in Becton, Dickinson and by 173.1% in the second quarter. Montag & Caldwell LLC now owns 516,821 shares of the medical instruments supplier’s stock worth $100,837,000 after buying an additional 327,587 shares during the period. Institutional investors and hedge funds own 87.43% of the company’s stock.

A number of brokerages have weighed in on BDX. Stifel Nicolaus reaffirmed a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Cowen and Company reaffirmed a “buy” rating and set a $230.00 target price on shares of Becton, Dickinson and in a research note on Monday, August 14th. Barclays PLC reaffirmed an “equal weight” rating and set a $210.00 target price (up previously from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Finally, Zacks Investment Research downgraded shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Monday, August 7th. One analyst has rated the stock with a sell rating, five have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Becton, Dickinson and has an average rating of “Buy” and a consensus price target of $196.93.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at 195.34 on Friday. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $206.63. The company has a market cap of $44.45 billion, a P/E ratio of 56.57 and a beta of 1.06. The company’s 50 day moving average is $199.43 and its 200 day moving average is $191.33.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. During the same quarter in the prior year, the company posted $2.35 earnings per share. Becton, Dickinson and’s revenue for the quarter was down 5.1% compared to the same quarter last year. On average, equities research analysts predict that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be given a dividend of $0.73 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.49%. Becton, Dickinson and’s payout ratio is 83.43%.

In related news, insider Nabil Shabshab sold 6,149 shares of the stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $201.76, for a total transaction of $1,240,622.24. Following the completion of the sale, the insider now owns 15,648 shares of the company’s stock, valued at $3,157,140.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gary M. Cohen sold 15,512 shares of the stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the sale, the insider now directly owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. Insiders have sold 75,904 shares of company stock valued at $15,242,688 in the last three months. 1.40% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/16/becton-dickinson-and-company-bdx-shares-bought-by-bank-of-new-york-mellon-corp.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.